In conclusion, higher TILs and PD-L1+TILs in pre-NAT specimens may also forecast the effectiveness of neoadjuvant trastuzumab with chemotherapy for HER2-positive breast cancer, in accordance with our findings. Here, ERBB2 is linked to breast carcinoma.